Plug Pulled on Cancer Clinical Trial: Sudden End for $18 Million Push by California Stem Cell Agency
Caladrius stock price plummets -- Google graphic
California’s ambitious, $18 million effort to develop -- in relatively short order -- a stem cell therapy for a deadly form of skin cancer collapsed abruptly last week, apparently the victim of “excessively long development timelines.”
Caladrius Biosciences, Inc., the recipient of the California funding, te…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.